Skip to main content
Celgene amends protocols for midstage study of CAR T candidate bb2121

Several changes to protocols have been reported by Celgene with regard to its midstage trial to test the efficacy of its chimeric antigen receptor T-cell therapy bb2121 to treat patients with relapsed or refractory multiple myeloma. Amended protocols include raising the dosage to be administered and increasing the number of participants to 140.

Full Story: